IceCure Medical (NASDAQ:ICCM) Earns “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of IceCure Medical (NASDAQ:ICCM) in a research note released on Thursday, Benzinga reports. The firm currently has a $2.50 price target on the stock.

IceCure Medical Stock Performance

Shares of ICCM stock opened at $0.62 on Thursday. IceCure Medical has a 12 month low of $0.52 and a 12 month high of $1.57. The stock has a market capitalization of $28.28 million, a P/E ratio of -1.88 and a beta of 0.56. The company has a current ratio of 2.97, a quick ratio of 2.54 and a debt-to-equity ratio of 0.03. The firm’s 50 day moving average is $0.68 and its 200 day moving average is $0.94.

IceCure Medical (NASDAQ:ICCM) last announced its quarterly earnings results on Tuesday, August 20th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.01. IceCure Medical had a negative return on equity of 111.27% and a negative net margin of 410.22%. The firm had revenue of $1.01 million for the quarter, compared to analysts’ expectations of $0.90 million. During the same period in the prior year, the business posted ($0.09) earnings per share. On average, sell-side analysts anticipate that IceCure Medical will post -0.27 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in IceCure Medical stock. Renaissance Technologies LLC purchased a new position in IceCure Medical Ltd (NASDAQ:ICCM) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 66,400 shares of the company’s stock, valued at approximately $49,000. Renaissance Technologies LLC owned about 0.15% of IceCure Medical as of its most recent SEC filing. 0.62% of the stock is currently owned by institutional investors.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.